Examkin

Question

Difficulty: Very hardInfectious Diseases

An infectious diseases consultation is requested for a 5959-year-old male inpatient. He was admitted 44 days ago with severe back pain and fever, leading to a diagnosis of T10−T11\text{T10}-\text{T11} vertebral osteomyelitis and an associated epidural abscess. Urgent surgical decompression and debridement were performed on the day of admission. Blood cultures obtained prior to antibiotic administration, as well as intraoperative tissue specimens, have both grown Staphylococcus aureus. Susceptibility testing confirms the isolate is susceptible to oxacillin, cefazolin, vancomycin, and daptomycin. The patient has been receiving empiric intravenous vancomycin therapy since presentation. His medical history includes type 22 diabetes mellitus and hypertension. 33 years ago, he experienced a severe allergic reaction following a dose of oral amoxicillin; he rapidly developed diffuse urticaria, wheezing, and facial angioedema, which necessitated emergency administration of intramuscular epinephrine. He has no prior exposure to cephalosporin antibiotics. Currently, his vital signs are stable, and his serum creatinine is 0.9 mg/dL0.9 \text{ mg/dL}. Based on current guidelines, which of the following is the most appropriate next step in the pharmacologic management of this infection?

  1. A
    Discontinue vancomycin and start intravenous oxacillin
  2. B
    Continue intravenous vancomycin
  3. Discontinue vancomycin and start intravenous cefazolinAnswer
  4. D
    Discontinue vancomycin and start intravenous daptomycin
  5. E
    Discontinue vancomycin and start intravenous linezolid

Answer

The most appropriate next step is to discontinue vancomycin and start intravenous cefazolin.
The correct answer is to switch the patient to intravenous cefazolin. This patient has a severe infection caused by methicillin-susceptible Staphylococcus aureus (MSSA). For MSSA infections, anti-staphylococcal beta-lactams (such as cefazolin) are significantly superior to vancomycin, demonstrating faster clearance of bacteremia, lower rates of clinical failure, and reduced mortality. Although this patient has a history of IgE-mediated anaphylaxis to amoxicillin (a penicillin), cefazolin is remarkably safe to administer. Cross-reactivity between penicillins and cephalosporins is not caused by the core beta-lactam ring itself, but rather by similarities in the R1 side chains. Cefazolin possesses a unique R1 side chain that is structurally distinct from all penicillins and almost all other cephalosporins. Therefore, it does not cross-react with penicillins, and current infectious disease and allergy guidelines strongly recommend the direct administration of cefazolin for MSSA infections in patients with penicillin anaphylaxis, without the need for prior skin testing or desensitization.

Step-by-Step Solution

1
Identify the pathogen and determine the optimal class of antibiotics for targeted therapy.
The patient has a severe, deep-seated infection (osteomyelitis and epidural abscess) caused by Methicillin-susceptible Staphylococcus aureus (MSSA).
For invasive MSSA infections, anti-staphylococcal beta-lactams (e.g., cefazolin, nafcillin, oxacillin) are the gold standard, as they provide vastly superior bactericidal activity compared to vancomycin, resulting in lower clinical failure and mortality rates.
2
Assess the impact of the patient's severe amoxicillin allergy on beta-lactam selection.
The patient had an IgE-mediated anaphylactic reaction to amoxicillin. Therefore, all penicillins (including oxacillin and nafcillin) are strictly contraindicated due to shared structural determinants.
Amoxicillin and oxacillin share the core penicillin beta-lactam structure, posing an unacceptably high risk of a recurrent life-threatening allergic reaction.
3
Evaluate the safety profile of cefazolin in the context of penicillin anaphylaxis.
Cefazolin can be safely administered to this patient despite the history of amoxicillin anaphylaxis.
Cross-reactivity between penicillins and cephalosporins is driven almost entirely by structural similarities in the R1 side chains, not the beta-lactam ring itself. Cefazolin possesses a completely unique R1 side chain that does not cross-react with penicillins or amoxicillin. Current guidelines recommend direct administration of cefazolin without prior testing in this scenario.

Key Concept

Patients with severe MSSA infections should be treated with an anti-staphylococcal beta-lactam rather than vancomycin to improve survival. Cefazolin possesses a unique R1 side chain and does not cross-react with penicillins, making it the preferred and safe definitive therapy even in patients with a history of severe, IgE-mediated anaphylaxis to penicillins.
Rate this question

Topics

Infectious Diseases

More questions from this topic